Oral Anticoagulants in Severe Renal Dysfunction

Chapter
First Online:

Abstract

When choosing an anticoagulant for a patient with chronic kidney disease (CKD), consider that patients with CKD were excluded from landmark direct oral anticoagulant (DOAC) trials if their creatinine clearance (CrCl) was <25–30 mL/min, but use of these agents has been approved in patients with a CrCl as low as 15 mL/min based on extrapolated data. Limited data suggests that warfarin is beneficial and relatively safe in patients with CKD and atrial fibrillation.

Keywords

Non-dialysis dependent chronic kidney disease Severe chronic kidney disease Atrial fibrillation Anticoagulation Direct oral anticoagulant Warfarin Stroke risk Bleeding risk 
This is a preview of subscription content, log in to check access.

References

  1. 1.
    You JJ, Singer DE, Howard PA, et al. Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e531S–75S.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Ng KP, Edwards NC, Lip GY, et al. Atrial fibrillation in CKD: balancing the risks and benefits of anticoagulation. Am J Kidney Dis. 2013;62(3):615–32.CrossRefPubMedGoogle Scholar
  3. 3.
    Providencia R, Marijon E, Boveda S, et al. Meta-analysis of the influence of chronic kidney disease on the risk of thromboembolism among patients with nonvalvular atrial fibrillation. Am J Cardiol. 2014;114(4):646–53.CrossRefPubMedGoogle Scholar
  4. 4.
    Inker LA, Astor BC, Fox CH, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis. 2014;63(5):713–35.CrossRefPubMedGoogle Scholar
  5. 5.
    Morrill AM, Ge D, Willett KC. Dosing of target-specific oral anticoagulants in special populations. Ann Pharmacother. 2015;49(9):1031–45.CrossRefPubMedGoogle Scholar
  6. 6.
    Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093–104.CrossRefPubMedGoogle Scholar
  7. 7.
    Wilhelm SM, Kale-Pradhan PB. Estimating creatinine clearance: a meta-analysis. Pharmacotherapy. 2011;31(7):658–64.CrossRefPubMedGoogle Scholar
  8. 8.
    Winter MA, Guhr KN, Berg GM. Impact of various body weights and serum creatinine concentrations on the bias and accuracy of the Cockcroft-Gault equation. Pharmacotherapy. 2012;32(7):604–12.CrossRefPubMedGoogle Scholar
  9. 9.
    Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–51.CrossRefPubMedGoogle Scholar
  10. 10.
    Lehr T, Haertter S, Liesenfeld KH, et al. Dabigatran etexilate in atrial fibrillation patients with severe renal impairment: dose identification using pharmacokinetic modeling and simulation. J Clin Pharmacol. 2012;52(9):1373–8.CrossRefPubMedGoogle Scholar
  11. 11.
    Fox KA, Piccini JP, Wojdyla D, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J. 2011;32(19):2387–94.CrossRefPubMedGoogle Scholar
  12. 12.
    Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–92.CrossRefPubMedGoogle Scholar
  13. 13.
    Hohnloser SH, Hijazi Z, Thomas L, et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J. 2012;33(22):2821–30.CrossRefPubMedGoogle Scholar
  14. 14.
    Savaysa® [package insert], Parsippany, NJ: Daiichi Sankyo, Inc.; 2015Google Scholar
  15. 15.
    Eliquis® [package insert], Princeton, NJ: Bristol-Myers Squibb Company; 2015Google Scholar
  16. 16.
    Pradaxa® [package insert], Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; 2015Google Scholar
  17. 17.
    Xarelto® [package insert], Titusville, NJ: Janssen Pharmaceuticals, Inc.; 2016Google Scholar
  18. 18.
    Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–91.CrossRefPubMedGoogle Scholar
  19. 19.
    Bonde AN, Lip GY, Kamper AL, et al. Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study. J Am Coll Cardiol. 2014;64(23):2471–82.CrossRefPubMedGoogle Scholar
  20. 20.
    Nimmo C, Wright M, Goldsmith D. Management of atrial fibrillation in chronic kidney disease: double trouble. Am Heart J. 2013;166(2):230–9.CrossRefPubMedGoogle Scholar
  21. 21.
    Sakaan SA, Hudson JQ, Oliphant CS, et al. Evaluation of warfarin dose requirements in patients with chronic kidney disease and end-stage renal disease. Pharmacotherapy. 2014;34(7):695–702.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.Department of PharmacotherapyUniversity of Utah College of PharmacySalt Lake CityUSA

Personalised recommendations